NCT00302159View on ClinicalTrials.gov

Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2013

Study Completion Date

November 30, 2014

Conditions
High Grade GliomasBrain Tumors
Interventions
PROCEDURE

adjuvant therapy

DRUG

Temozolomide

Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.

DRUG

Valproic Acid

Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.

RADIATION

Radiation therapy

External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.

Trial Locations (3)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

23284

Virginia Commonwealth University, Richmond

19104-6056

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00302159 - Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors | Biotech Hunter | Biotech Hunter